This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Kwak, E. L. Articles by Haber, D. A. Search for Related Content PubMed PubMed Citation Articles by Kwak, E. L. Articles by Haber, D. A.

Mammary Tumorigenesis following Transgenic Expression of a Dominant Negative CHK2 Mutant

¹ Massachusetts General Hospital Cancer Center and Harvard Medical School, Charlestown, Massachusetts and ² Center for Comparative Medicine, University of California-Davis, Davis, California

Requests for reprints: Daniel A. Haber, Massachusetts General Hospital Cancer Center, CNY-7 Building 149, 13th Street, Charlestown, MA 02129. Phone: 617-726-7805; Fax: 617-724-6919; E-mail: Haber{at}helix.mgh.harvard.edu.

A truncating allele of the cell cycle checkpoint kinase CHK2 is present in 1% of the population, conferring a moderate increase in breast cancer risk, and inactivation of chk2 enhances mammary tumorigenesis in mice with targeted inactivation of brca1. We used the mouse mammary tumor virus (MMTV) promoter to target expression of a kinase-dead CHK2 allele (D347A). Mammary tumors, of predominantly micropapillary histology, developed in 40% of MMTV-CHK2-D347A transgenic mice with an average latency of 20 months. Tumors metastasized to lung and spleen; tumor-derived cell lines were frequently aneuploid and showed suppression of irradiation-induced p53 function. Primary hematopoietic malignancies were also observed in the spleen, another site of MMTV expression. The increased rate of tumor formation in MMTV-CHK2-D347A mice, compared with the relatively low incidence in chk2-null mice, provides a model to study modifiers of CHK2-dependent transformation. (Cancer Res 2006; 66(4) 1923-8)

This article has been cited by other articles:

				H. Takemura, V. A. Rao, O. Sordet, T. Furuta, Z.-H. Miao, L. Meng, H. Zhang, and Y. Pommier Defective Mre11-dependent Activation of Chk2 by Ataxia Telangiectasia Mutated in Colorectal Carcinoma Cells in Response to Replication-dependent DNA Double Strand Breaks J. Biol. Chem., October 13, 2006; 281(41): 30814 - 30823. [Abstract] [Full Text] [PDF]

				Y. Pommier, J. N. Weinstein, M. I. Aladjem, and K. W. Kohn Chk2 molecular interaction map and rationale for chk2 inhibitors. Clin. Cancer Res., May 1, 2006; 12(9): 2657 - 2661. [Abstract] [Full Text] [PDF]